Fluorescein Sodium and Benoxinate Hydrochloride

Manufacturer
Bausch & Lomb Incorporated | Alliance Medical Products, Inc. (dba Siegfried Irvine)
Effective date
2025-05-12
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 21:33:06

Label at a glance#

ProductFluorescein Sodium and Benoxinate Hydrochloride
Active ingredientFLUORESCEIN SODIUM, BENOXINATE HYDROCHLORIDE
Label structure14 sections

Indications and uses

Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent.

Dosage and administration

Instill 1 to 2 drops topically in the eye as needed.

Storage and handling

Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is supplied as a sterile, aqueous, topical ophthalmic solution with a fill volume of 5 mL in a 6 mL amber glass bottle and a black polypropylene cap with a sterilized rubber dropper bulb and glass pipette. NDC 24208-734-05 Storage: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light. After opening, can be stored up ...

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Instill 1 to 2 drops topically in the eye as needed.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is a yellow to orange-red ophthalmic solution containing fluorescein sodium 2.6 mg/mL (0.3%) and benoxinate hydrochloride 4.4 mg/mL (0.4%).

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is contraindicated in patients with known hypersensitivity to any component of this product.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Corneal Toxicity

SPL UNCLASSIFIED SECTION

Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage with accompanying visual loss.

5.2 Corneal Injury Due to Insensitivity

SPL UNCLASSIFIED SECTION

Patients should not touch the eye for approximately 20 minutes after using this anesthetic as accidental injuries can occur due to insensitivity of the eye.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following serious ocular adverse reactions are described elsewhere in the labeling:

The following adverse reactions have been identified following use of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4%: ocular hyperemia, burning, stinging, eye irritation, blurred vision and punctate keratitis. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Risk Summary

There are no available data on the use of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% in pregnant women to inform any drug associated risk.

Adequate animal reproduction studies have not been conducted with fluorescein sodium and/or benoxinate hydrochloride. Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% should be given to a pregnant woman only if clearly needed.

8.2 Lactation

LACTATION SECTION

Risk Summary

There are no data on the presence of fluorescein sodium or benoxinate hydrochloride in human milk after ocular administration of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4%, the effects on the breastfed infant, or the effects on milk production.

The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4%, and any potential adverse effects on the breastfed infant from Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4%.

8.4 Pediatric Use

PEDIATRIC USE SECTION

The safety and effectiveness of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% have been established for pediatric patients. Use of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is supported in pediatric patients by evidence from adequate and well controlled studies.

8.5 Geriatric Use

GERIATRIC USE SECTION

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

11 DESCRIPTION

DESCRIPTION SECTION

Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is a sterile solution containing a disclosing agent in combination with a short-acting ester anesthetic for topical ophthalmic use.

Fluorescein sodium is represented by the following structural formula:

ChemFluorescein
ChemFluorescein

Chemical Name: 3’,6’ Dihydroxy-3H-spiro[isobenzofuran-1,9-xanthen]-3-one disodium salt.

Benoxinate hydrochloride is represented by the following structural formula:

ChemBenoxinate
ChemBenoxinate

Chemical Name: 2-(Diethylamino) ethyl 4-amino-3-butoxybenzoate hydrochloride.

Each mL of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution 0.3%/0.4% contains:

  • Active ingredients:fluorescein sodium 2.6 mg (0.3%) equivalent to fluorescein 2.3 mg (0.2%), benoxinate hydrochloride 4.4 mg (0.4%) equivalent to benoxinate 3.9 mg (0.4%)
  • Preservative:chlorobutanol 12.6 mg (1.3%)
  • Inactive ingredients:povidone, hydrochloric acid, boric acid, water for injection. Hydrochloric acid may be added to adjust pH (4.3 – 5.3).

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.2 Pharmacodynamics

PHARMACODYNAMICS SECTION

Maximal corneal anesthesia usually occurs in about 5-45 seconds and lasts about 20 minutes after single administration. The anesthetic effect may be extended by subsequent administration 10-20 minutes after the last administration.

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Studies to evaluate the mutagenic or carcinogenic potential of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% have not been conducted. Studies to evaluate impairment of fertility have not been conducted.

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

Controlled clinical studies in adults and pediatric patients have demonstrated that topical administration of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% enables visualization and corneal anesthesia sufficient to enable applanation tonometry, tear fluid dynamics evaluation and short conjunctival and corneal procedures. Maximal corneal anesthesia usually occurs in about 5-45 seconds and lasts about 20 minutes after single administration.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is supplied as a sterile, aqueous, topical ophthalmic solution with a fill volume of 5 mL in a 6 mL amber glass bottle and a black polypropylene cap with a sterilized rubber dropper bulb and glass pipette.

NDC 24208-734-05

Storage:Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light. After opening, can be stored up to one month if stored at room temperature or until the expiration date on the bottle if stored in refrigerated conditions. Keep tightly closed.

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Accidental Injury Precaution

Advise patients not to touch their eyes for approximately 20 minutes after application. Their eyes will be insensitive due to the effect of the anesthetic, and care should be taken to avoid accidental injuries.

Distributed by:
Bausch & Lomb Americas Inc.
Bridgewater, NJ 08807 USA

Manufactured by:
Siegfried-Irvine
Irvine, CA 92618 USA

Patented. See patents.bausch.comfor US patent information.

© 2022 Bausch & Lomb Incorporated or its affiliates

9785500

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC24208-734-05

Fluorescein Sodium

and Benoxinate

Hydrochloride

Ophthalmic Solution

0.3%/0.4%

(Sterile)

FOR TOPICAL OPHTHALMIC USE

[Eye Image]

Rx only5 mL

BAUSCH + LOMB

9785301

carton
carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
2287005benoxinate HCl 0.4 % / fluorescein sodium 0.3 % Ophthalmic SolutionPSN3
2287005benoxinate hydrochloride 4 MG/ML / fluorescein sodium 3 MG/ML Ophthalmic SolutionSCD3
2287005benoxinate hydrochloride 0.4 % / fluorescein sodium 0.3 % Ophthalmic DropsSY3

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
FLUORESCEIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
8f43a274-9585-47cb-b427-0eb3e578384dProduct name120250623
4a998fa9-995e-4ea5-97ef-93a559305758Product name120200706
c94ccba7-2a03-4a3e-a891-d62a57340fb2Product name120180215

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
24208-734-05Fluorescein Sodium and Benoxinate Hydrochloride5 mL in 1 BOTTLE, GLASSSOLUTION/ DROPS53
24208-734-05Fluorescein Sodium and Benoxinate Hydrochloride1 in 1 CARTONSOLUTION/ DROPS13

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
24208-734FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE SOLUTION/ DROPS [BAUSCH & LOMB INCORPORATED]3Current NDC, Legacy NDC, 2 package rows20250514_1797c5ef-66c4-4cf8-b62d-b484242be2ee.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
24208-73424208-734-05

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML · Source PDF

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDEBENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09

Orange Book patents#

Current patent rows page 1 of 1 · 3 matching rows.

Application-product, Patent, Expiration table
Application-productPatentExpirationUse codeCoverage / statusSubmission date
N211039-001102930472037-11-15U-2755Drug product2020-03-19
N211039-001106321972037-11-15U-2755Drug product2020-05-22
N211039-001108428722037-11-15U-30012020-12-18

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-0984e616aacf4f…
2026-08-18 06:07:402026-07N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-0931067a03dcf5…
2025-08-23 18:47 UTC2025-08N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-096a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-0903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-092680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-095bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-0979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-091e350fbaab3a…
2024-05-31 18:47 UTC2024-05N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-098072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-095c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-095d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-094b0b4de00fa7…
2022-03-09 01:35 UTC2022-03N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-0987673890dc5c…
2021-03-12 10:30 UTC2021-03N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-095aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-098869cabd3fbd…
2020-11-12 02:37 UTC2020-11N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09c0c555d07b60…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-096a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-091c564ffb4f44…
2023-12-20 04:57 UTC2023-12N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-099b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-093f0d92c62455…
2023-05-13 08:27 UTC2023-05N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09053a50430f4f…
2023-01-26 05:58 UTC2023-01N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-093bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-093a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N211039-001FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE0.4%;0.3%SOLUTION/DROPS / OPHTHALMICRLD, RS2020-03-09a50c72e98297…

Observed Orange Book patent history#

Patent history page 1 of 3 · 115 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productPatentExpirationUse codeCoverage / statusSubmission dateSource SHA-256
2026-09-14 22:38:342026-08N211039-001102930472037-11-15U-2755Drug product2020-03-1984e616aacf4f…
2026-09-14 22:38:342026-08N211039-001106321972037-11-15U-2755Drug product2020-05-2284e616aacf4f…
2026-09-14 22:38:342026-08N211039-001108428722037-11-15U-30012020-12-1884e616aacf4f…
2026-08-18 06:07:402026-07N211039-001102930472037-11-15U-2755Drug product2020-03-19caaa826d4ba7…
2026-08-18 06:07:402026-07N211039-001106321972037-11-15U-2755Drug product2020-05-22caaa826d4ba7…
2026-08-18 06:07:402026-07N211039-001108428722037-11-15U-30012020-12-18caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N211039-001102930472037-11-15U-2755Drug product2020-03-19011fe1cb6892…
2026-02-19 14:30 UTC2026-02N211039-001106321972037-11-15U-2755Drug product2020-05-22011fe1cb6892…
2026-02-19 14:30 UTC2026-02N211039-001108428722037-11-15U-30012020-12-18011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N211039-001102930472037-11-15U-2755Drug product2020-03-1931067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N211039-001106321972037-11-15U-2755Drug product2020-05-2231067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N211039-001108428722037-11-15U-30012020-12-1831067a03dcf5…
2025-08-23 18:47 UTC2025-08N211039-001102930472037-11-15U-2755Drug product2020-03-196a471c1ec25d…
2025-08-23 18:47 UTC2025-08N211039-001106321972037-11-15U-2755Drug product2020-05-226a471c1ec25d…
2025-08-23 18:47 UTC2025-08N211039-001108428722037-11-15U-30012020-12-186a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N211039-001102930472037-11-15U-2755Drug product2020-03-19fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N211039-001106321972037-11-15U-2755Drug product2020-05-22fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N211039-001108428722037-11-15U-30012020-12-18fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N211039-001102930472037-11-15U-2755Drug product2020-03-19b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N211039-001106321972037-11-15U-2755Drug product2020-05-22b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N211039-001108428722037-11-15U-30012020-12-18b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N211039-001102930472037-11-15U-2755Drug product2020-03-1903ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N211039-001106321972037-11-15U-2755Drug product2020-05-2203ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N211039-001108428722037-11-15U-30012020-12-1803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N211039-001102930472037-11-15U-2755Drug product2020-03-192680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N211039-001106321972037-11-15U-2755Drug product2020-05-222680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N211039-001108428722037-11-15U-30012020-12-182680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N211039-001102930472037-11-15U-2755Drug product2020-03-195bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N211039-001106321972037-11-15U-2755Drug product2020-05-225bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N211039-001108428722037-11-15U-30012020-12-185bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N211039-001102930472037-11-15U-2755Drug product2020-03-19d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N211039-001106321972037-11-15U-2755Drug product2020-05-22d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N211039-001108428722037-11-15U-30012020-12-18d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N211039-001102930472037-11-15U-2755Drug product2020-03-19d06236e962d9…
2024-10-29 15:01 UTC2024-10N211039-001106321972037-11-15U-2755Drug product2020-05-22d06236e962d9…
2024-10-29 15:01 UTC2024-10N211039-001108428722037-11-15U-30012020-12-18d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N211039-001102930472037-11-15U-2755Drug product2020-03-1979d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N211039-001106321972037-11-15U-2755Drug product2020-05-2279d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N211039-001108428722037-11-15U-30012020-12-1879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N211039-001102930472037-11-15U-2755Drug product2020-03-19301d65b070ca…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Fluorescein Sodium and Benoxinate HydrochlorideFLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDEBausch & Lomb Incorporated1797c5ef-66c4-4cf8-b62d-b484242be2ee2025-05-12Warnings, Adverse reactionsExact identifier
ndc (package): 24208-734-05
ndc (product): 24208-734
ndc11 (package): 24208073405
spl id: 34f4eb14-b40e-1d6d-e063-6394a90a3e3b
spl set id: 1797c5ef-66c4-4cf8-b62d-b484242be2ee

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.